Abiomed Introducer Kit Recall: Auditing the Records Behind a Thrombus Claim

A recall tells you a product was pulled. The chart tells you what happened to one patient, in what order.

When a Class I recall lands on a cardiovascular device, the first calls into a firm are rarely about the device. They are about a specific patient who developed a clot, and whether that clot has anything to do with the product.

That is a harder question than the headline suggests. Thrombus, meaning a blood clot formed inside a vessel or a device lumen, is a documented risk of prolonged intravascular support in critically ill patients. It appears in the literature, in device labeling, and in the consent forms. So the recall does not answer the question. It only makes the question worth asking.

This is where medical record review earns its place. Not by deciding what caused the clot, which belongs to the retained physician and to counsel, but by producing a clean, sourced timeline of what the records document and, just as important, what they do not.

What the FDA actually classified, and when

The FDA classified the recall of Abiomed 14Fr Low Profile Introducer Kits as Class I on July 17, 2026. Class I is the FDA's most serious category, used when a device may cause serious injury or death if use continues.

The sequence matters more than the single date that circulated in the press:

• May 22, 2026. Abiomed initiated the recall and notified customers.
• June 2, 2026. The FDA published an early alert about the risk.
• July 17, 2026. The FDA classified the recall as Class I.
• August 3, 2026. Trade and association coverage picked it up, which is where most people first saw it.

The stated reason is thrombus formation during prolonged use. In the FDA's wording, thrombus may form within the indwelling sheath lumen or in the annular gap between the sheath inner diameter and the catheter outer diameter during prolonged support, which may disrupt blood flow near the access site. The listed potential consequences include peripheral vessel obstruction, ischemia, vascular occlusion requiring intervention, and permanent vascular damage if a clot dislodges during support or removal.

The affected product codes include 1000434 (14 Fr x 13 cm) and 1000435 (14 Fr x 25 cm) for the Impella CP, along with 1000542 and the Impella CP with SmartAssist set 1000413. The kits are compatible only with 10th generation Impella CP with SmartAssist pumps, so those pumps were pulled in with the kits. Customers were told to quarantine affected product, return it, notify staff, and alert other facilities that received kits.

Source Credit: US Food and Drug Administration, Medical Device Recalls, Abiomed 14Fr Low Profile Introducer Kits, Class I classification July 17, 2026; American Hospital Association news coverage, August 3, 2026.

Why a clot in this population is contested from the start

Thrombus in a mechanical circulatory support patient is difficult to attribute because almost every element of the clinical picture is itself a clotting risk. The patient is usually in cardiogenic shock or undergoing high risk coronary intervention. Blood is moving through a pump. A large bore sheath sits in a femoral artery for hours or days. Anticoagulation is being titrated against bleeding risk, often in a patient who is also bleeding somewhere.

Any defense will say so, and the literature supports the general point. So a claim that rests on the recall alone does not go far. What moves it is specificity: which vessel, which side, at what hour, on what anticoagulation, with what pressures and pulse checks documented before and after, and with what imaging.

A useful way to think about it: correlation in a timeline is not causation. Two events sitting near each other in the chronology do not prove one produced the other. The reviewer's job is to place them accurately and flag the relationship. The conclusion belongs to the qualified expert.

The records that carry the sequence

For an Impella CP support case, the cath lab log is the starting point, not the whole file. The 14Fr introducer is the access sheath for temporary mechanical circulatory support, which means the patient spent most of the relevant hours in an ICU, not in the procedure suite. A record request built only around catheterization documentation will miss the period in which the risk accrued.

The set that usually matters:

• Procedure and cath lab records. Access site and side, sheath size and length, insertion and removal times, operator notes, fluoroscopy and angiographic findings, and any access complications noted at the table.
• Device and support records. Pump placement, purge solution and rate, alarms, position changes, P level adjustments, total support duration, and explant documentation.
• ICU nursing flowsheets. Distal pulse and Doppler checks, limb color, temperature and sensation, capillary refill, site assessments, and the frequency at which those checks were charted.
• Anticoagulation records. Heparin or bivalirudin orders, rate changes, hold times, and the corresponding aPTT, anti-Xa or ACT results with their draw times.
• Imaging and vascular studies. Duplex ultrasound, CT angiography, and any operative reports for thrombectomy, embolectomy, fasciotomy or revascularization.
• Device accountability documentation. Lot and serial numbers, implant logs, biomedical or materials management records, recall notices received by the facility, and any return or quarantine paperwork.

That last category is the one most often left out of an initial request, and it is the one that ties a specific patient to a specific recalled lot. Without it, everything else is a well organized story about an unidentified device. A medical chronology built from the full set puts the lot number, the sheath dwell time, the anticoagulation record and the first documented perfusion change on one line of sight.

Building the timeline so it survives contact with the defense

A defensible support-case timeline is built around dwell time and documented change, not around narrative. Four anchors carry most of the work.

The first anchor is insertion. Exact time, access site, side, sheath product code and lot, and the baseline distal vascular assessment charted before or immediately after access. If a baseline pulse check is missing, that absence needs to be visible in the deliverable, not smoothed over.

The second is dwell. Total hours the sheath was indwelling, mapped against the FDA's own language about prolonged support. Every position change, alarm and purge interruption sits on this line.

The third is the first documented change. Not the diagnosis of thrombus, but the first charted deviation: a diminished or absent pulse, a cool or mottled limb, a rising lactate, a new pain complaint, an alarm pattern. In many charts this appears in a nursing flowsheet hours before it appears in a physician note. The gap between those two entries is itself a finding worth flagging.

The fourth is intervention and outcome. Imaging that confirmed the occlusion, the procedure performed, the vessel involved, and the functional result documented in later notes and therapy records.

Around those anchors sits the part clients underestimate: the missing-record check. A history can look complete until one absent transfer summary, one unretrieved outside imaging study, or one gap in flowsheet charting changes the sequence entirely. A missing record is a missing piece of the picture, and in a device case the missing piece is usually the one the other side finds first. If the volume or the retrieval scope is still unclear, a quick record review cost estimate is a reasonable first step before the file grows.

What the review flags, and what it does not decide

LezDo TechMed extracts, organizes and presents the medical evidence documented in the records so that attorneys, physicians, evaluators and other qualified decision makers can conduct their analysis more efficiently. In a device case, that means the review flags things like these:

• The sheath dwell time and how it compares against the duration language in the recall notice.
• Lot or serial identifiers present in the chart, and where they are absent.
• Anticoagulation gaps, holds, and results that fall outside ordered ranges, with their timestamps.
• Intervals where documented vascular checks are missing or charted less frequently than ordered.
• Inconsistencies between the nursing flowsheet, the physician note and the procedure record on the same event.
• Prior vascular history, peripheral arterial disease, prior thrombotic events, smoking history and other documented conditions that the defense will raise.

What the review does not do is decide whether the introducer kit caused the clot. That is a causation determination. It belongs to the retained cardiologist, vascular surgeon or interventionalist, and to counsel arguing the case. Any vendor offering to prove device causation from a chart is telling you something that should worry you.

The practical benefit is narrower and more useful: the expert gets a sourced, page-cited sequence instead of eleven hundred pages, and can spend the retainer on opinion rather than on assembly.

Questions worth asking before the file is ordered

• Do we have the facility's device accountability records, not just the clinical chart?
• Did we request the ICU flowsheets in native or full-resolution form, or only the discharge summary and procedure notes?
• Do we have every anticoagulation lab result with draw times, not just the daily values?
• Was the patient transferred between facilities during support, and do we have both charts?
• Do we have the recall notice as it was received by this specific facility, with its date?

The bottom line

The Abiomed introducer kit recall is a real Class I event with a documented mechanism, and it gives counsel a legitimate reason to pull a file and look closely. It is not, on the current public record, a mass event. Three serious injuries and six impacted US hospitals is a narrow footprint, and a firm that builds intake messaging around a mass tort scale it cannot yet support is taking on avoidable risk.

What holds up in either scenario is the same discipline. Get the full record set, including device accountability. Build the timeline around insertion, dwell, first documented change and intervention. Flag the gaps out loud. Then hand a clean, sourced chronology to the expert who is qualified to say what it means.

An analysis is only useful if it supports a decision. In a device case, the decision is whether there is a case at all, and that gets made faster when the records are organized before anyone starts arguing about them.